Department of Internal Medicine, Bozyaka Training and Research Hospital, Izmir, Turkey.
Arch Gynecol Obstet. 2010 Mar;281(3):539-43. doi: 10.1007/s00404-009-1189-7. Epub 2009 Aug 5.
The present study was designed to determine the effect of oral contraceptives (OCP) and OCP plus spironolactone (Sp) on plasma soluble CD40L levels in polycystic ovary syndrome (PCOS) patients.
Fifty-six women with PCOS were randomized into two treatment protocols: ethinylestradiol + cyproterone acetate (2 mg, EE/CA; n = 28), and EE/CA with spironolactone (Sp; n = 28). Plasma sCD40L levels were measured before and after a 3-month treatment.
Before the initiation of treatment, the sCD40L levels were not significantly different between the groups [EE/CA (1.33 ng/mL) vs. EE/CA + Sp (1.23 ng/mL); P > 0.05]. In the post-treatment period, sCD40L concentrations were increased compared with pre-treatment values in the EE/CA and EE/CA + Sp groups (1.33 vs. 2.70 ng/mL, P = 0.011; and 1.23 vs. 2.41 ng/mL, P = 0.017; respectively).
Increased plasma concentrations of sCD40L are associated with OCP and OCP + Sp treatment regimens in PCOS patients.
本研究旨在探讨口服避孕药（OCP）和 OCP 加螺内酯（Sp）对多囊卵巢综合征（PCOS）患者血浆可溶性 CD40L 水平的影响。
56 名 PCOS 患者随机分为两组治疗方案：炔雌醇环丙孕酮（2mg，EE/CA；n = 28）和 EE/CA 加螺内酯（Sp；n = 28）。治疗前和治疗 3 个月后测量血浆 sCD40L 水平。
治疗前，两组 sCD40L 水平无显著差异[EE/CA（1.33ng/mL）与 EE/CA+Sp（1.23ng/mL）；P＞0.05]。在治疗后期间，与治疗前相比，EE/CA 和 EE/CA+Sp 组的 sCD40L 浓度均升高（1.33 与 2.70ng/mL，P = 0.011；1.23 与 2.41ng/mL，P = 0.017）。
PCOS 患者中，血浆可溶性 CD40L 浓度的升高与 OCP 和 OCP+Sp 治疗方案有关。
